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Aurora kinases are a group of serine/threonine kinases responsible for the regulation of 
mitosis. In recent years, with the increase in Aurora kinase-related research, the 
important role of Aurora kinases in tumorigenesis has been gradually recognized. 
Aurora kinases have been regarded as a new target for cancer therapy, resulting in the 
development of Aurora kinase inhibitors. The study and application of these small-
molecule inhibitors, especially in combination with chemotherapy drugs, represents a 
new direction in cancer treatment. This paper reviews studies on Aurora kinases from 
recent years, including studies of their biological function, their relationship with tumor 
progression, and their inhibitors. 
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1. INTRODUCTION 
Mitosis is a precise and orderly process that is strictly regulated. During the process 
of cell proliferation, to correctly pass the genetic information from the parental cell to 
the daughter cells, accurate cell division is very important to maintain the body's 
stability. If regulatory factors encounter a problem, cell division will be abnormal, 
leading to tumorigenesis. The mitotic process primarily depends on three mechanisms: 
protein localization, protein hydrolysis, and substrate phosphorylation. These 
mechanisms are regulated by mitotic kinases [1, 2]. Mitotic kinases are divided into 
tyrosine kinases and serine/threonine kinases. Mitotic kinases can implement 
intracellular signal transduction by phosphorylating downstream substrates at specific 
sites, thereby completing the cell cycle. In recent years, a novel family of 
serine/threonine protein kinases, Aurora kinases, was discovered. Aurora kinases are 
involved in the regulation of mitotic checkpoints, centrosome maturation and 
separation, spindle assembly and maintenance, chromosome segregation and 
cytokinesis, playing a key role in the cell cycle [3, 4]. Previous studies have shown that 
Aurora kinases have an important relationship with tumorigenesis and tumor 
development through chromosomal instability. Aurora kinases can be vital targets in 
the development of anticancer drugs [5, 6]. 
 
2. BIOLOGICAL FUNCTIONS OF AURORA KINASES 
Aurora kinases were originally discovered by David Glover in Drosophila [7] and by 
Bischoff and Zhou in human [8, 9]. To date, three family members, Aurora-A, -B, and -C, 
have been identified in mammalian genomes. Aurora kinases are all nucleoproteins, 
with different cellular locations and different functions [10]. Aurora kinase family 
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members are evolutionarily conserved in structure. Aurora-A, -B, and -C proteins are 
composed of 403, 344, and 309 amino acids, respectively. Regarding secondary 
structure, they have a conserved N-terminal regulatory domain and C-terminal catalytic 
domain. The sequences of the regulatory domains of the Aurora kineases show no 
similarity, while the sequences of the catalytic domain are highly homologous. In the 
catalytic domain, the similarity of Aurora-A and -B is 57%, the similarity of Aurora-B 
and -C is 75%, and the similarity of Aurora-A and -C is 60%. This high conservation is 
important for the specificity of the substrates and inhibitors [11]. Aurora-A contains a 
catalytic kinase domain, an activated T-loop, a degradation domain (D-box) and D-box 
activation domain (DAD). Aurora-B and -C do not contain DAD. 
 
2.1. Aurora-A 
Aurora-A was the first member to be discovered and is the most important member, 
with the encoding gene located on chromosome 20q13.2. During cell cycle progression, 
Aurora-A is mainly located around the central body in prophase; it is on the 
microtubules near the spindle pole in metaphase; and it is located on the polar 
microtubules in anaphase and telophase, where it plays an important role in 
centrosome maturation, spindle assembly, and mitosis. Aurora-A phosphorylates a large 
number of substrates, including p53, Polo-like kinase-1 (PLK1), Cell division cycle 25B 
(CDC25B), Breast cancer 1 (BRCA1), Centrin, Large tumor suppressor kinase 2 (LATS2), 
Guanine nucleotide exchange factor-H1 (GEF-H1), Transforming acidic coiled-coil 
containing protein 3 (TACC3), NudE neurodevelopment protein 1 like 1 (NDEL1), 
Histone deacetylase 6 (HDAC6), SKI proto-oncogene (Ski), Hepatoma up-regulated 
protein (HURP), Serine/threonine protein phosphatase 1 (PP1), Targeting protein for 
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Xklp2 (TPX2), Eg5, histone H3, Centromere protein-A (CENP-A), CENP-E, Centrosomal 
protein 192 (CEP192), Cytoplasmic polyadenylation element binding protein (CPEB), 
LIM domain kinase 1 (LIMK1), LIMK2, SRC, Ras like proto-oncogene A (RalA), AKT, and 
polycystin 2 (PC2) [12]. Aurora-A-mediated phosphorylation of substrates contributes 
to the activation of kinase activity, protein degradation, protein stabilization, targeting 
of the centrosome, maturation and separation of centrosome, translocation, and 
negative regulation of protein function [12]. The expression and distribution of Aurora-
A during mitosis are strictly regulated under normal circumstances [13-15]. Aurora-A 
expression starts to increase in late S phase, reaches a peak in G2/M phase, and begins 
to decrease after G1 phase [13-15]. The protein level of Aurora-A is regulated by the 
ubiquitin-proteasome system. Indeed, in early G1, Aurora-A protein is degraded via the 
ubiquitin ligase APC/C (anaphase-promoting complex/cyclosome) and its co-activator 
Cdh1 is involved [16, 17]. Proposed requirements for Aurora-A ubiquitylation are 
recognition of the C-terminal D-box by Cdh1 [18] and an additional A-box/DAD motif in 
Xenopus Aurora-A [19, 20]. Furthermore, it has been suggested that Ser53 (equivalent 
to Ser51 in human Aurora-A) of the A-box is phosphorylated during mitosis and that 
phosphorylation on Ser53 (or 51 in human) is essential for the mitotic stabilization of 
Xenopus [21] and human Aurora-A [22, 23].   
Injection of an anti-Aurora-A antibody or interference with the biological effect of 
Aurora-A can inhibit centrosome separation at the single stage of the spindle, causes 
G2-M phase arrest, and induces apoptosis in HeLa cells [24, 25]. In addition, by 
phosphorylating Geminin at Thr25, Aurora-A can prevent its degradation via 
ubiquitination, enhances its stability, and ensures the formation of the pre-replication 




The gene encoding Aurora-B is located on chromosome 17p13.1, and its catalytic 
domain shows 71% similarity with Aurora-A; however, their locations and functions are 
different. Aurora-B is located on the centromere in prophase and metaphase; once the 
cell enters anaphase, it is located in the central portion of the spindle on the equatorial 
plane; and in telophase, it is located in the furrow and the central body [10]. The main 
functions of Aurora-B are phosphorylating histone H3, recruiting chromatin during 
prophase, arranging and segregating the chromosomes, regulating mitotic checkpoints, 
and regulating cytokinesis [24, 28, 29]. Aurora-B can form a tetramer with Survivin, 
Borealin and inner centromere protein (INCENP); this tetramer, termed the 
chromosomal passenger complex (CPC), regulates chromosome segregation and 
cytokinesis [30-32]. Tow groups have shown that protein level of Aurora-B is controlled 
by APCCdh1, in similar to Aurora-A [33, 34]. However, in our previous study, Aurora-B 
expression level did not change after co-transfection with Cdh1 [23]. Moreover, E32A 
and E32S mutants (Glu32 correspond to Ser51 of Aurora-A) of Aurora-B were degraded 
by APCCdh1, strongly suggesting that Aurora-B may not be degraded because of 
phosphorylation mimicking at Glu32 [23]. To know the detailed mechanism of Aurora-B 
degradation, further studies will be required. 
 
2.3. Aurora-C 
The gene encoding Aurora-C is located on chromosome 19q13 and is highly 
expressed in testis, with little expression in other normal tissues [35-37]. Aurora-C and 
-B show 83% similarity in the catalytic domain, with the same location and similar 
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functions. During mitosis, Aurora-C is located on the chromosome in prophase and on 
the centromere in metaphase. Aurora-C is transferred to the central portion of the 
spindle in anaphase and is located in the central body during cytokinesis [38]. Together, 
Aurora-C and -B regulate chromosome segregation and cytokinesis. In addition, Aurora-
C and -B were co-immunoprecipitated [37], and Aurora-C can save polyploid cells with 
Aurora-B depletion or null induction of Aurora-B [36]. To date, Aurora-C has rarely 
been investigated, and its functions require further elucidation. 
 
3. THE ROLE OF AURORA KINASES IN THE OCCURRENCE AND DEVELOPMENT OF 
TUMORS 
Aurora kinases are a group of serine/threonine kinases responsible for the 
regulation of mitosis. If the expression of an Aurora kinase is abnormal, errors may 
occur in the mitotic signaling pathway, resulting in uncontrolled cell proliferation, an 
abnormal number of cellular chromosomes, or a change in their order. These 
phenomena can lead to cell death or can transform. The overexpression of Aurora 
kinases is frequently observed in a variety of solid tumors and hematological tumors 
and is associated with poor prognosis [6, 28]. 
 
3. 1. The role of Aurora-A in tumors 
The gene encoding Aurora-A is located on 20q13.2, a chromosomal segment 
characterized by translocations, deletions, or active amplification, showing natural 
instability. Aurora-A is closely related to human malignancies. Nishida et al. found that 
the overexpression of Aurora-A was associated with chromosomal instability in colon 
cancer [39]. Other studies reported that in hepatocellular carcinoma and gastric cancer, 
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the overexpression of Aurora-A could predict an abnormal number of chromosomes 
and poor prognosis [40, 41]. In addition, the high expression of Aurora-A is related to 
malignant behaviors in a variety of tumors, including breast, prostate, bladder, ovary, 
and pancreatic cancer. The overexpression of Aurora-A indicates abnormal cytokinesis 
and centrosome amplification, resulting in aneuploidy or genomic instability and 
leading to tumorigenesis [39-43]. These phenomena can regulate the mitogen-activated 
protein kinase (MAPK) pathway by epithelial-mesenchymal transition and stem cell 
reprogramming, thereby inducing distant metastasis [44]. Aurora-A can also 
phosphorylate the p53 gene in vivo, thus breaking the balance between the hydrolysis of 
ubiquitinated proteins and the transcriptional activity of p53 [45]. Aurora-A kinase is 
involved in a number of important processes, such as the constituent to 
RAS/RAF/MEK/ERK/MAP kinase pathway of carcinogenesis [46]. Moreover, Aurora-A 
influences the growth rate of cancer cells, stimulates telomerase activity, and promotes 
collagen I-induced cell migration [46]. 
 
3. 2. The role of Aurora-B in tumors 
Aurora-B is highly expressed in various cancers, including colon cancer, liver cancer, 
thyroid cancer, head and neck squamous cell carcinoma (HNSCC), and breast cancer, 
and is related to indicators of malignancy, such as the tumor type and lymph node 
metastasis [47, 48]. In addition, as a member of the CPC, Aurora-B can jointly regulate 
chromosome segregation and cytokinesis together with Survivin, Borealin and INCENP 
[30-32]. Our previous studies demonstrated that i) Aurora-B is highly expressed in 
colon cancer and oral squamous cell carcinoma (OSCC), and ii) Aurora-B expression is 
associated with cell proliferation and malignant behaviors. Additionally, cases with high 
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expression of both Aurora-B and Survivin were more severe in the degree of malignancy 
[49-52], indicating that components of the CPC may interact with each other to jointly 
promote the tumorigenesis and tumor development. 
 
3. 3. The role of Aurora-C in tumors 
Aurora-C is highly expressed in the tumor cell lines, such as HeLa, HepG2, MDA-MB-
453 and HUH7 [53]. Moreover, Aurora-C is highly expressed in colon, breast, and 
prostate cancer [36]. We speculate that Aurora-C as well as Aurora-A and -B may play a 
certain role in the tumorigenesis and tumor development. However, its specific 
mechanism in the molecular pathways in tumorigenesis is not fully elucidated, and 
further research in this area is required. 
 
In summary, overexpression of Aurora kinases is closely related to a large range of 
tumors. Therefore, Aurora kinases are excellent targets for cancer therapy. In addition, 
because Aurora-A and -B are expressed and activated only during mitosis, they are 
ineffective for non-proliferating cells. Thus, compared to other non-specific cytotoxic 
drugs, inhibitors targeting Aurora-A and/or -B have the advantage of mild adverse 
reactions and good tolerance. Therefore, Aurora kinase inhibitor can be an ideal drug 
for cancer therapy. 
 
4. AURORA KINASE INHIBITORS 
To date, a variety of Aurora kinase inhibitors have been developed, and some of 
them have entered clinical trials, showing good anti-tumor activity [54]. As Aurora 
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kinases are highly expressed in a variety of tumors, Aurora proteins can serve as 
anticancer targets to develop a variety of small-molecule inhibitors. The current study 
showed that the Aurora-A, -B, and -C proteins had amino acid sequences of different 
lengths and amino-termini with different characteristics; however, their ATP-binding 
sites were highly homologous [55]. Small-molecule inhibitors that inhibit the activity of 
Aurora kinases by targeting the ATP-binding site have become the main direction of 
development for Aurora kinase inhibitors. Aurora kinase inhibitors are divided into 
pan-Aurora kinase inhibitors and selective Aurora kinase inhibitors, and they are 
developed for the treatment of various cancers, including myeloid leukemia, non-
Hodgkin's lymphoma, melanoma, colon cancer, and HNSCC. Aurora kinase inhibitors are 
listed in Table 1. 
 
4.1. Pan-Aurora kinase inhibitors 
Pan-Aurora kinase inhibitors include AMG 900, PHA-680632, VX-680, VE-465, 
Reversine, CCT1337690, CCT129202, CHR-3520, SNS-314, AKI-001 and ZM447439. 
Multikinase inhibitors, including KW-2449, CYC116, R763, XL-228, PHA-739358, JNJ-
7706621, SU-6668, AT-9283 and PF-03814735 also inhibit Aurora kinases. These 
molecules are described in detail below. 
 
4.1.1. AMG 900 
AMG 900 is an orally available pan-Aurora kinase inhibitor and inhibits Aurora-A, -
B, and -C with half-maximal inhibitory concentration (IC50) values of 5, 4, and 1 nM, 
respectively [56]. AMG 900 cross-reacts with other kinases, including p38α, TYK2, JNK2, 
MET, and TIE2. AMG 900 inhibits auto-phosphorylation of Aurora-A at Thr288 and 
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histone H3 phosphorylation at Ser10 in a dose-dependent manner. Interestingly, AMG 
900 inhibits the proliferation of various cancer cells, including cells resistant to the 
antimitotic drug paclitaxel and to other aurora kinase inhibitors (AZD1152, MK-0457, 
and PHA-739358), at low concentrations [56]. Moreover, TP53 loss-of-function 
mutations and low baseline p21 protein levels were significantly associated with 
increased sensitivity to AMG 900 [57]. As various drug-resistant cancers exhibits TP53 
mutations or downregulation, it is interesting to use AMG900 in drug-resistant cancers. 
Importantly, AMG-900 has great potential to overcome both the tumor multidrug 
resistance and to show activity in cancers resistant to other Aurora kinase inhibitors 
due to mutation of the Aurora-B binding site. Currently two Phase I studies are 
underway in patients with advanced solid tumors and acute myeloid leukemia. 
 
4.1.2. PHA-680632 
PHA-680632 identified from the combinatorial expansion of the 1,4,5,6-
tetrahydropyrrolo[3,4-c]pyrazole bi-cycle, a novel and versatile scaffold designed to 
target the ATP pocket of protein kinases [58]. PHA-680632 inhibits Aurora-A, -B, and -C 
with IC50 values of 27, 135, and 120 nM, respectively [59]. PHA-680632 cross-reacts 
with FGFR1 [59]. PHA-680632 is active on a wide range of cancer cell lines and shows 




VX-680 (MK-0457/Tozasentib) was designed during the SAR exploitation of a lead 
molecule amino pyrazole linked to 2-substituted quinazoline [60]. VX-680 can 
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specifically bind to the ATP-binding domain, thus inhibiting its activity. VX-680 showed 
long-lasting inhibition of Aurora-A, -B, and -C with the IC50 values of 0.6, 18 and 4.6 nM, 
respectively [61]. VX-680 can inhibit the proliferation of multiple tumor cell lines, 
including breast cancer, cervical cancer, colon cancer, leukemia, melanoma, pancreatic 
cancer, and prostate cancer [62]. In addition to inhibiting the Aurora kinase family, VX-
680 can effectively inhibit the BCR-ABL and JAK-2 kinases, with broad-spectrum pre-
clinical anti-tumor activity. In murine xenograft models, VX-680 could inhibit the 
tumorigenesis of acute myeloblastic leukemia, pancreatic cancer, and colon cancer cells 
[61]. VX-680 was the first Aurora kinase inhibitor to be used in patients. Open-label 
Phase I/II clinical trial reveals that this compound is active in leukemia patients with 
BCR-ABL T315I mutations [63]. This study reveals that 8 of 18 chronic myelogenous 
leukemia patients with T315I-BCR/ABL mutations had hematologic responses during 
the treatment. Despite the positive response with the drug, all the clinical trials 
involving VX680 were discontinued due to QTc prolongation occurred in one patient. 
The efficacy of VX680 alone and in combination with other chemotherapeutic 
compounds is still being evaluated in various preclinical models. A recent studies 
showed that i) VX680 is effective in human hepatoblastoma cells [64], and ii) 
combination of VX680 with methotrexate and cisplatin induces either additive or 
synergistic growth inhibition in human osteosarcoma and hepatocellular carcinoma 
cells [65, 66].  
 
4.1.4. VE-465 
VE-465 was designed by SAR optimization of the lead amino pyrazole. The chemical 
structure is similar to that of VX-680. VE-465 inhibits Aurora-A, -B, and -C with Ki values 
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of 1, 26, and 8.7 nM, respectively by ATP competitive binding assays [67]. In preclinical 
studies, VE-465 exhibited anticancer effects on hepatocellular carcinomas. In addition, 




Reversine (2-(4-morpholinoanilino)-N6-cyclohexyladenine) is a substituted purine 
analogue and was originally shown to promote the dedifferentiation of myotubes 
derived from the murine myoblast cell line C2C12 [69]. Reversine inhibits Aurora-A and 
-B activities by 80% and Aurora-C by 55% at a concentration of 0.5 μM [66]. The crystal 
structure of the reversine-Aurora-B kinase complex shows that reversine is a novel 
class of ATP-competitive Aurora kinase inhibitors [70]. Reversine inhibits multiple 
myeloma cells, to suppress the kinase activity of Aurora-A, -B, JAK2, and SRC [71]. In 
addition, reversine suppresses the proliferation of human oral squamous cells via cell 
cycle arrest, polyploidy, and/or apoptosis induction [72]. 
 
4.1.6. CCT137690 
CCT137690 is a newly synthesized compound, which has been shown to inhibit the 
activities of Aurora kinases. CCT137690 inhibits Aurora-A, -B, and -C with IC50 values of 
15 ± 3 μM, 25 μM, and 19 μM, respectively [73]. CCT137690 has shown promising 
therapeutic effects on cancer cells, including colon cancer, neuroblastoma, and acute 




CCT129202 was developed through SAR optimization of an imidazopyridine 
scaffold and has high activity against Aurora-A and -B. CCT129202 inhibits Aurora-A, -B, 
and -C with IC50 values of 42, 198, and 27 nM, respectively [76]. CCT129202 cross-
reacts with FGFR3, PDGFRβ (platelet-derived growth factor receptor), and GSK3β 
(glycogen synthase kinase 3 beta) at high concentrations. CCT129202 inhibits the 
growth of several human cancer cell lines [76]. 
 
4.1.8. CHR-3520 
After screening many small molecule inhibitors, Chroma selected CHR-3520 for 
entry into pre-clinical development during 2006. CHR-3520 is a potent inhibitor of 
Aurora kinases along with several other kinases that are important for the growth and 
development of tumors. Details of the specificity and cellular potency of CHR-3520 in 
relation to the AKs have not yet been disclosed [77]. 
 
4.1.9. SNS-314 
SNS-314 was designed from the lead molecule, 2-aminoethyl phenyl benzamide via 
structure-activity optimizations. SNS-314 inhibits Aurora-A, -B, and -C with IC50 values 
of 9, 31, and 3 nM, respectively [78]. In addition, SNS-314 inhibits 24 other kinases with 
higher IC50 values. SNS-314 inhibits cell proliferation in various human cell lines and 
induces polyploidy. The antiproliferative activity of SNS-314 was attributed to Aurora 
kinase inhibition, as observed by the inhibition of auto-phosphorylation of the Aurora 
kinases and histone H3 phosphorylation [79]. SNS-314 has been subjected to a Phase I 
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clinical trial involving advanced solid tumor patients [80]. 
 
4.1.10. AKI-001 
AKI-001 is a potent Aurora kinase inhibitor, which exhibits low nanomolar potency 
against both Aurora-A and -B (IC50 < 100 nM). AKI-001 was discovered by high- 
throughput screening against Aurora-A kinase [81]. Further optimization and inclusion 
of lactam ring and hydrocarbon constraint to pentacyclic scaffold led to the discovery of 
the highly potent AKI-001, which is orally bioavailable phthalazine derivative with 
improved enzyme and cellular activity and a high level of kinase selectivity. AKI-001 
inhibits the proliferation of various cancer cell lines. 
 
4.1.11. ZM447439 
ZM447439 was the first reported Aurora kinase inhibitor [82]. As a quinazoline 
derivative, ZM447439 can inhibit both Aurora-A and -B with IC50 values of 110 nM and 
130 nM, respectively. In HeLa, A549, MCF-7, and DLD1 cells, ZM-447439 can regulate 
chromosome arrangement, cell division, and mitosis checkpoints as well as kill 
proliferating cells with no effect on non-proliferating cells currently showing no obvious 
clinical progression [82, 83]. 
 
4.1.12. KW-2449 
KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase. 
KW-2449 was identified by screening the chemical libraries of Kyowa Hakko Kirin using 
several leukemia cells, which have several activated mutations in FLT3 or BCR-ABL 
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translocation [84]. Indeed, KW-2449 has an antiproliferative activity against various 
types of leukemia. KW-2449 acts by targeting Fms-like tyrosine kinase 3 (FLT3), ABL, 
ABL-T315I mutant, Aurora-A and -B. KW-2449 inhibited Aurora-A with IC50 of 48 nM 
and Aurora-B with the equivalent potency [84]. Oral administration of KW-2449 
showed dose-dependent inhibition of tumor growth in FLT3-mutated xenograft model 
84]. Moreover, KW-2449 in combination with HDAC inhibitors increases lethality in 
Bcr/Abl+ leukemia cells [85]. Two Phase I trial of KW-2449 in leukemia patients were 
terminated due to suboptimal dosing schedule and failure to identify a tolerable dose 
that had potential for efficacy. 
 
4.1.13. CYC116 
CYC116 is an orally available Aurora kinase inhibitor that which was discontinued 
from Phase I clinical trials. CYC116 was designed from the subset of lead N-phenyl-4-
(thiazol-5-yl) pyrimidin-2-amines via cell-based screening of kinase-directed compound 
library [86]. CYC116 inhibits Aurora-A, -B, and -C with IC50 values of 44, 19, and 65 nM, 
respectively [87]. In addition, CYC116 inhibits VEGFR2 (vascular endothelial growth 
factor receptor 2) with an IC50 of 69 nM [87]. CYC116 is a targeted drug that has 
antimitotic and anti-angiogenesis properties [86]. Indeed, CYC116 induces failed 
mitosis, resulting in polyploidy via suppressed autophosphorylation of Aurora-A and -B 
in lung cancer cells [86]. Further, CYC116 exhibited antitumor activity in various 
leukemia, solid tumor xenograft and leukemic syngenic models [86]. It recently has 
been revealed that resistance to CYC-116 treatment is mediated via serine 
hydroxymethyltransferase by comparing the protein composition of CYC-116-sensitive 
and -resistant HCT116 colon cancer cell, suggesting that it may be a good target to 
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overcome resistance in combination therapy [88]. 
 
4.1.14, R763/AS703569 
R763 (AS703569) is an orally available Aurora kinase inhibitor, currently in Phase I 
study. R763 was designed and developed based on an image-based phenotypic screen. 
R763 inhibits Aurora-A, -B, and -C with IC50 values of 4, 4.8, and 6.8 nM, respectively 
[89]. In addition, R763 inhibits Abl, FLT1 (fms-related tyrosine kinase), and FLT3 
kinases. R763 has potent anti-proliferative activity against many cell types 
accompanying unique phenotypic changes such as enlarged cell size, endoreduplication 
and apoptosis [89]. Oral administration of R763 markedly inhibits tumor growth in 
xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia 
[89]. Previous studies showed that R763 has significant antitumor activity in single-
agent Phase I studies [90, 91]. Several preclinical data indicated that the combination of 




XL228 is a protein kinase inhibitor targeting IGF1R, the AURORA kinases, FGFR1-3, 
ABL and SRC family kinases [92, 93]. Particularly promising in the field of leukemia, XL-
228 harbors activity against a mutant form of Abl, T315I, which is largely resistant to 
imatinib and dasatinib in chronic myelogenous leukemia (CML). It is being evaluated in 




PHA-739358 is a class of tricyclic tetrahydropyrrolo pyrazole compounds which 
had previously been identified as an ATP-mimetic pharmacophore suited for kinase 
binding [94]. The structure activity relationship (SAR) analysis of several 
pyrrolopyrazole subclasses resulted in the synthesis of PHA-680632, which showed 
high anti-cancer activity both in vitro and in vivo [94]. Through combinatorial expansion 
of a related 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core and SAR refinements of the 5-
amido-pyrrolopyrazole series a potent Aurora kinase inhibitor PHA-739358 was 
identified [95]. PHA-739358 inhibits Aurora-A, -B, and -C with IC50 values of 13, 79, and 
61 nM, respectively [95]. PHA-739358 cross-reacts with ABL, showing inhibitory 
activity against the T315I mutant with BCR/ABL mutations [96]. Moreover, PHA-
739358 cross-reacts with Abl (Abelson), Ret (rearranged during transfection), Trk-A, 
and FGFR1 (fibroblast growth factor receptor 1) kinases at high concentrations, [97]. 
Clinical trials of PHA-739358 involving solid tumors and hematological malignancies of 
chronic myeloid leukemia with imatinib resistance showed good drug tolerance and 
clinical efficacy [98-100]. 
 
4.1.17. JNJ-7706621 
JNJ-7706621 was designed by the refinement of a series of acyl-substituted 1,2,4-
triazole-3,5-diamine analogues [101]. JNJ-7706621 inhibits Aurora-A and -B with IC50 
values of 11 and 15 nM, respectively [102]. In addition, JNJ-7706621 inhibits CDK1 
(cyclin dependent kinases), CDK2, CDK3, CDK4, and CDK6. JNJ-7706621 inhibits the 
proliferation of various cancer cell lines, but showed less potency against normal cell 
lines. Interestingly, JNJ-7706621 inhibits cell proliferation of both drug-sensitive and 
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drug-resistant cancer cells. JNJ-7706621 has been subjected to preclinical in vivo testing 
using the human melanoma xenograft model [102].  
 
4.1.18. SU-6668/TSU-68/Orantinib 
SU6668 was originally designed as a selective inhibitor of receptor tyrosine kinases 
involved in tumor vascularization. SU6668 was characterized as an ATP-competitive 
inhibitor of the PDGFR, VEGFR2, and FGFR1 RTKs in vitro [103]. In cell-based assays, 
low concentrations of SU6668 effectively blocked autophosphorylation of βPDGFR and 
VEGFR2 [103]. In addition, SU6668 targets Aurora kinases and TANK-binding kinase 1 
[104]. SU6668 induced cell cycle arrest via inhibition of Aurora kinase activity and 
potently suppressed antiviral and inflammatory responses by interfering with TANK-
binding kinase 1–mediated signal transmission [104]. Recent reports show that SU6668 
is significantly more efficacious, when combined with either tumor irradiation or 
immune therapy [105, 106]. 
 
4.1.19. AT-9283 
AT9283 is the first Aurora kinase inhibitor discovered via the company’s 
proprietary fragment-based screening approach. The lead optimization was guided by 
X-ray crystallography and finally resulted in AT9283 as a clinical candidate [107]. 
AT9283 is a multi-targeted kinase inhibitor that inhibits tyrosine and serine/threonine 
kinases such as Aurora A and B, JAK-2 and JAK-3, Tyk2 and RSK2. AT9283 inhibits 
Aurora-A and -B with IC50 values of 3 nM [107]. The safety, tolerability, and 




PF-03814735 is orally available dual Aurora-A and Aurora-B inhibitor, which is 
currently in a Phase I study. PF-03814735 was discovered by SAR exploitation of lead 
pyrimidine scaffold. PF-03814735 was eventually designed by SAR optimizations at C2 
and C4 positions of pyrimidine scaffold [110]. PF-03814735 inhibits Aurora-A and 
Aurora-B with IC50 values of 5 and 0.8 nM, respectively. In addition, PF-03814735 
inhibits FLT1, FAK (focal adhesion kinase), TrkA, MET, and FGFR1 kinases at higher 
IC50 values [111]. PF-03814735 inhibits the proliferation of various human tumor cell 
lines. In Phase I initial clinical study, 57 patients with solid tumors were treated [112]. 
Now Phase I study has completed. In addition, small cell lung cancer (SCLC) is very 
sensitive to PF-03814735 among a diverse panel of 87 cancer cell lines. Particularly, the 
status of the Myc gene family significantly correlated with the efficacy of PF-03814735, 
suggesting that Myc family gene-driven SCLC and other malignancies are suitable 
indications for the treatment with PF-03814735 [113].  
 
4.2. Selective Aurora-A kinase inhibitors 
As mentioned above, both Aurora-A and -B play an important role in the 
tumorigenesis and tumor development, while Aurora-A and -B kinases are not 
distinguished as different therapeutic targets frequently, so it has not yet been 
determined which is the better target [54]. Previous studies have found that potential 
clinical consequences and the biological outcomes of inhibiting Aurora-A or -B are very 
dissimilar. They should be distinguished as two distinctive therapeutic targets that can 
be targeted independently. Therefore, selective Aurora kinase inhibitors are divided 
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into Aurora-A and -B kinase inhibitors, because of the different effects on cancers [108]. 
Selective Aurora-A inhibitors are described in detail below. 
 
4.2.1. MLN8054 
MLN8054 (Millennium) is an ATP-competitive and selective inhibitor of Aurora-A 
kinase (with IC50 values for Aurora-A and -B of 4 and 172 nM, respectively) [109]. The 
conformation change and the difference between the binding pockets for Aurora-A and -
B are key factors responsible for the selectivity [110]. MLN8054 is used for the 
treatment of solid tumors, including lymphomas. In a phase I clinical trial, orally 
administered MLN8054 was quickly absorbed, with the side effect of drowsiness [62]. 
Recently, MLN8054 was replaced by the second-generation Aurora kinase inhibitor, 
MLN8237, and clinical trials of MLN8054 were terminated due to sever somnolence and 
central nervous system toxicity [62]. 
 
4.2.2. MLN8237/Alisertib 
MLN8237 (alisertib) is an investigational, orally active, selective small molecule 
inhibitor of Aurora-A that is being investigated for the treatment of both heme-
lymphatic malignancies and solid tumors [111]. MLN8237 was designed through SAR 
optimization of lead 5- H-pyrimido[5,4-d][2]benzazepine. MLN8237 is approximately 
200-fold more selective for Aurora-A (IC50 = 6.7 nM) than Aurora-B (IC50 = 1,534 nM) 
in cell-based assays [111]. In both preclinical and clinical studies, MLN8237 has shown 
preliminary antitumor activity in heme-lymphatic malignancies [112-116]. Moreover, 
MLN8237 research has entered phase I and II clinical trials for the treatment of periodic 
epithelial ovarian cancer, fallopian tube cancer, early peritoneal cancer, advanced solid 
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tumors, and advanced types of blood malignancy [54]. MLN8237 can effectively 
improve the efficacy of chemotherapy to enhance its anti-tumor capacity. Data showed 
that after treatment, 49% of patients had a stable disease condition, 11% of patients 
achieved partial remission, and 13% of patients experienced relapse or remained 
uncured. In a study of chronic myeloid leukemia, MLN8237 could effectively kill T315I 
mutant cells by an independent BCR-ABL mechanism, although this type of cell can 
tolerate other targeted therapies [6, 59]. In addition, the combination of MLN8237 and 
nilotinib significantly enhanced the therapeutic effect [6, 59]. 
 
4.2.3. ENMD-2076 
ENMD-2076 was designed by SAR optimization of a lead imidazole-vinyl-
pyrimidine scaffold. ENMD-2076 is an orally active, vinyl-pyrimidine-based compound. 
ENMD-2076 selectively inhibits Aurora-A with an IC50 of 14 nM by biochemical assays 
[117]. Moreover, ENMD-2076 inhibits multiple oncogenic kinases, including FLT3, Src, 
VEGFR2, and FGFR1, as well as the growth of various cancer cell lines [117]. Recently, 
ENMD-2076 has been shown to be highly effective against malignant melanoma and 
colon cancer cells [117-119]. Now Phase 2 studies are currently underway being tested 
in fibrolamellar carcinomas, triple-negative breast cancer, advanced/metastatic soft 
tissue sarcoma, and advanced ovarian clear cell carcinomas [120, 121]. 
 
4.2.4. VX-689/MK-5108 
 VX689 (MK-5108) has been studied in a Phase I clinical trial in patients with 
advanced solid tumors. VX-689 is a highly selective Aurora A inhibitor with IC50 of 
0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than 
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Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity [122]. Moreover, 
VX689 inhibits the proliferation of diverse cancer cell lines and significantly enhanced 
the efficacy of docetaxel in HeLa-S3 and ES-2 cell lines. It has completed Phase I testing 
in patients with advanced and/or refractory solid tumors as a single agent and in 
combination with docetaxel. 
 
4.2.5. TC-A 2317 hydrochloride 
TC-A 2317 hydrochloride is a potent Aurora-A inhibitor (Ki = 1.2 nM compared to 
101 nM for inhibition of Aurora-B) [123]. In addition, TC-A 2317 hydrochloride is 
selective over 60 other kinases (IC50 values > 1000 nM). TC-A 2317 hydrochloride was 
created by transforming 4-(5-methyl-3-pyrazoloamino)pyrimidine moiety of VX-680 to 
3-cyano-6-(5-methyl-3pyrazoloamino)pyridine. TC-A 2317 hydrochloride exhibited 
good cell permeability and effective antitumor activity. 
 
4.2.6. MP529 
MP-529 was designed to block the action of Aurora-A kinase by CLIMB drug 
discovery process, which is based on the clustering of representative chemical 
structures and pharmacophores that embody large virtual library of nearly 50 million 
compound structures [124]. The MP529 represents a novel scaffold, which improves 
upon the pharmacological activities of known Aurora kinase inhibitors. MP529 exhibits 
nanomolar activity or better against the Aurora-A kinase, and have been carried 
forward into ex vivo and in vivo evaluations. 
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4.2.7. Aurora-A inhibitor 1 
Aurora-A Inhibitor I is a 2,4-dianilinopyrimidine that selectively and potently 
inhibits Aurora-A kinase. Aurora-A Inhibitor I effectively inhibits the proliferation of 
various cancer cell lines including HCT116, HT29, HeLa and leukemia cell lines [125, 
126]. The Aurora-A selectivity of Aurora-A Inhibitor I against Aurora-B depends on a 
single amino acid (Thr217) of Aurora-A [127].  
 
4.3. Selective Aurora-B inhibitor 
Selective Aurora-B inhibitors are described in detail below. 
 
4.3.1. GSK1070916 
GSK1070916 is a reversible Aurora-B and -C inhibitor. GSK1070916 was designed 
from the various SAR refinements of a lead 7-azaindole series [134]. GSK1070916 
inhibits Aurora-B-INCENP and Aurora-C-INCENP with IC50 values of 3.5 and 6.5 nM, 
respectively. In addition, GSK1070916 cross-reacts with FLT1, TIE2 (tyrosine kinase 
with immunoglobulin-like and EGF-like domains 1), SIK (salt inducible kinase), FLT4, 
and FGFR1 at higher concentrations [135]. GSK1070916 inhibits the proliferation of 
various cancer cell lines [136]. Interestingly, GSK1070916 showed no effects on non-
proliferating HUVEC cells. Phase I clinical study is currently completed in patients with 
advanced solid tumors.  
 
4.3.2. BI 811283 
BI 811283 is an Aurora-B inhibitor that is currently in a Phase II clinical study. BI 
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811283 inhibits Aurora-B with IC50 value of 9 nM and inhibits the proliferation of 
various cancer cell lines with an IC50 value <14 nM [137]. In Phase I dose escalation 
study, BI 811283 has been tested in advanced and metastatic solid tumors [138]. A 
Phase II clinical study in combination with cytarabine has completed in previously 
untreated AML ineligible for intensive treatment. 
 
4.3.3. Hesperadin 
Hesperadin is the first generation Aurora kinase inhibitor. Treatment of cancer cell 
lines with hesperadin resulted in Aurora-B inhibition phenotype. The specificity of 
hesperadin towards Aurora-A and -C is unknown. Most of the basic functions of Aurora-
B in mitosis and its role in cancer cell proliferation were discovered by inhibiting it with 
Hesperadin [139].  
 
4.3.4. AZD-1152 
AZD-1152 is a pyrazole quinazoline-dihydrogen phosphate derivative. AZD-1152 
was designed and developed from the lead pyrazole-acetanilide-substituted quinazoline 
by SAR exploitation [140]. As a selective inhibitor of Aurora-B (with IC50 values in the 
inhibition of Aurora-A, -B, and -C of 687, 3.7 and 17 nM, respectively), AZD-1152 can be 
quickly converted into the active drug AZD1152-hydroxyquinazoline pyrazole anilides 
(HQPA) in plasma [141], showing activity against a number of solid tumors (colon, 
breast, and lung cancer as well as myelogenous leukemia in xenograft models) [142]. 
Non-clinical studies showed that AZD1152 could weaken the phosphorylation of 
histone H3 and cell cycle progression with abnormal mitosis [143], suggesting that 
phosphorylated histone H3 can be used as a biomarker of the inhibition of Aurora-B 
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kinase. Studies have also shown that combination therapy of AZD-1152 with 
dexamethasone could significantly increase the activity of myeloma inhibition [143]. 
Additionally, AZD-1152 can be synergistically used with vincristine, daunorubicin, and 
other commonly used conventional anticancer drugs to enhance their anti-proliferative 
activity [140]. Initial clinical study was conducted on 13 patients having colon cancer, 
melanoma or some other solid tumors [144]. AZD1152 recently entered Phase I/II 
clinical trials focusing on its safety, tolerability, pharmacokinetics, and efficacy profiles 
in AML patients [145]. Currently, Phase I testing of AZD1152 in patients with diffuse 
large B-cell lymphoma and advanced solid malignancies is in progress.  
 
5. EXPRESSION AND TREATMENT WITH AURORA KINASES IN HNSCC  
The overexpression of Aurora-A mRNA and protein in HNSCC is closely related to 
tumor type, lymph node metastasis, and prognosis (5). Studies have shown that the 
overexpression of Aurora-A was not due to the overexpression of its mRNA; instead, it 
was due to protein phosphorylation inhibiting the ubiquitin-mediated degradation of 
Aurora-A protein. In HNSCC, the phosphorylation of Ser51 in Aurora-A can inhibit 
protein degradation mediated by APCCdh1, leading to protein accumulation in cancer 
cells, reflected as overexpression [23]. Furthermore, the overexpression of Aurora-A 
results in genomic instability and formation of aneuploidy, eventually leading to cancer. 
The elevated expression of Aurora-A is closely related to a poor disease outcome and a 
high risk of metastasis. Moreover, Aurora-A polymorphism has also been regarded as a 
genetic risk factor for the occurrence and development of esophageal tumors [146]. 
Aurora-B has been rarely investigated in HNSCC. It has been reported that the 
overexpression of Aurora-B in OSCC is related to cell proliferative activity, lymph node 
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metastasis and poor prognosis [49, 52]. The nuclear expression levels of Aurora-B and 
Survivin are closely related in OSCC, and cases with high expression levels of both are 
associated with cell proliferation and malignancy, suggesting that the co-expression of 
both promotes the occurrence and development of HNSCC [49]. 
In HNSCC, high expression of both Aurora-A and EGFR are shown [146]. Owning to 
Aurora-A/-B polymorphism, the efficiency of treatment with the EGFR inhibitory 
antibody, cetuximab varies significantly. Aurora-A/-B genotypically homozygous HNSCC 
cells react to cetuximab treatment, whereas heterozygous cells do not. It has been 
described that Aurora-A/-B knockdown or treatment with Aurora kinase inhibitor can 
abolish cetuximab resistance [146]. The combination of anti-Aurora-A/-B targeting and 
cetuximab in HNSCC cells improves the efficiency of treatment, compared to an 
individual therapy [67]. Then, a new and efficient therapeutic strategy comes: the 
combination of Aurora kinase inhibitor, the monoclonal antibody cetuximab and chemo-
radiotherapy [54, 146]. 
Moreover, in consideration of close interactions between Aurora-B and Survivin in 
cancer, and the premise that Survivin inhibitor YM155 has been used in clinical trials 
currently (e.g., in solid tumors (phase I) and advanced NSCLC (phase II)), the 




The Aurora kinase family plays an important role in the cell cycle, and abnormal 
expression of Aurora kinases is a key factor in tumorigenesis. Researchers consider 
Aurora kinases as excellent targets for anticancer drugs. Therefore, targeted drugs with 
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high efficiency and low toxicity have been developed. To date, a variety of Aurora kinase 
inhibitors have entered clinical studies, with some success. Aurora kinase inhibitors 
also show some disadvantages. For example, their efficacy against solid tumors is not 
satisfactory. With in-depth research on the Aurora kinase family, the prospect of Aurora 
inhibitors in the future is expected in the field of cancer research. As the effective 
anticancer drugs were not developed for HNSCC treatment, the development of target 
therapy drugs including Aurora kinase inhibitors are expected. 
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PHA-680632 Aurora-A/-B/-C FGFR1 C28H35N7O2 Nerviano/Pfizer Italia Phase 2
Chronic myelocytic leukemia, Hormone refractory prostate cancer, Multiple
myeloma
VX-680/MK-0457/Tozasentib Aurora-A/-B/-C BCR-ABL, JAK2 C23H28N8OS Vertex/Merck Phase 1, Phase 2
(Terminated)
Non-small cell lung carcinoma, Solid cancer,  Hematological malignancies
VE-465 Aurora-A/-B/-C - structure analog of
MK-0457
Merck Preclinical Hepatocellular carcinoma cell lines, Paclitaxel-resistant ovarian carcinoma
Reversine Aurora-A/-B/-C JAK2, SRC C21H27N7O The Scripps Research Institute Phase 2  Acute myeloid leukemia
CCT137690 Aurora-A/-B/-C - C26H31BrN8O Cambridge Research Institute Preclinical Colorectal cancer, Neuroblastoma , Acute myeloid leukemia
CCT129202 Aurora-A/-B/-C FGFR3, PDGFRβ, GSK3β C23H25ClN8OS Chroma Preclinical Solid tumors
CHR-3520 Aurora-A/-B/-C - - Chroma Preclinical -
SNS-314 Aurora-A/-B/-C Several kinases C19H19ClN6O4S3 Sunesis phase I Solid tumors, Leukemia
AKI-001 Aurora-A/-B/-C - C21H24N4O Roche Preclinical Solid tumors
ZM-447439 Aurora-A/ -B - C29H31N5O4 AstraZeneca Preclinical Solid tumor, Leukemia
KW-2449  FLT3, ABL, ABL-T315I, Aurora-
A/-B
- C20H20N4O Kyowa Hakko Kirin
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(Terminated)
Acute myelogenous leukemia, Acute lymphoblastic leukemia, Myelodysplastic
syndromes, Chronic myelogenous leukemia
CYC116 VEGFR2 Aurora-A/-B/-C C18H20N6OS Cyclacel Phase 1
(Terminated)
Solid tumor
R763/AS703569 Flt1, Flt3, Abl, Akt, VEGFR3 Aurora-A/-B/-C C24H30N7OF Rigel Phase 1 Solid tumor, Hematological malignancies
XL-228 IGF1R, FGFR1-3, ABL, SRC
family kinases, Aurora-A/-B/-C
- C22H31N9O Exelixis Phase 1 Ph+ leukemia, Multiple myeloma, Colorectal cancer
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Phase 1 Unspecified adult solid tumor, Multiple myeloma, Plasma cell neoplasm
Phase 2   Multiple myeloma
Phase 1 Solid tumor, Acute leukemia, Advanced solid tumor, Non-Hodgkin lymphoma
PF-03814735 FLT1, FAK, Trk-A, MET, FGFR1,
Aurora-A/-B
- C23H25F3N6O2 Pfizer Phase 1 Solid tumor
MLN8054 Aurora-A Aurora-B C25H15ClF2N4O2 Millennium Phase 1
(Terminated)
Advanced malignancies, Breast , Colon, Pancreatic, Bladder cancer
Phase 3 Peripheral T-cell lymphoma
Phase 2 Periodic epithelial ovarian cancer, Fallopian tube cancer, Early peritoneal
cancer, Advanced solid tumors, Advanced types of blood malignancy
Phase 2 Fibrolamellar carcinomas, Triple-negative breast cancer, Advanced/metastatic
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Phase 1 Acute myelogenous leukemia
VX-689/MK-5108 Aurora-A Aurora-B/-C, Trk-A C22H21ClFN3O3S Vertex/Merck Phase 1 Solid tumor, Neoplasm
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Hesperadin Aurora-B - C29H32N4O3S Boehringer Ingelheim Preclinical Research tool
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